Neolpharma Inc drugs

7 results

Adbry (tralokinumab-ldrm)

(tralokinumab-ldrm)
Neolpharma Inc
Usage: ADBRY is indicated for treating moderate-to-severe atopic dermatitis in adults and patients aged 12 and older when topical prescription therapies are inadequate or unsuitable. It can be administered with or without topical corticosteroids.
Neolpharma Inc
Usage: Dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate tablets are indicated for treating Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy, addressing symptoms that impair functioning in multiple settings. ADHD requires specific symptoms present before age 7 and significant impairment in social, academic, or occupational areas.

Enstilar (calcipotriene and betamethasone dipropionate)

(calcipotriene and betamethasone dipropionate)
Neolpharma Inc
Usage: Enstilar® (calcipotriene and betamethasone dipropionate) Foam is indicated for the topical treatment of plaque psoriasis in patients aged 12 years and older.

Levo-t (levothyroxine sodium)

(Levothyroxine Sodium)
Neolpharma Inc
Usage: LEVO-T is indicated for replacement therapy in congenital or acquired hypothyroidism and for pituitary thyrotropin suppression in managing well-differentiated thyroid cancer. It is not recommended for benign thyroid nodules or during subacute thyroiditis recovery.
Neolpharma Inc
Usage: Methylphenidate hydrochloride tablets are indicated for treating Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6 years and older, as well as for narcolepsy.
Neolpharma Inc
Usage: Oseltamivir phosphate is indicated for the treatment of acute, uncomplicated influenza A and B in patients aged 2 weeks and older, symptomatic for no more than 48 hours. It is also used for prophylaxis of influenza in individuals 1 year and older.

Taclonex (calcipotriene and betamethasone dipropionate)

(calcipotriene and betamethasone dipropionate)
Neolpharma Inc
Usage: Taclonex® Topical Suspension is indicated for the topical treatment of plaque psoriasis affecting the scalp and body in patients aged 12 years and older.